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Gestational diabetes mellitus (GDM) is a pregnancy disease 
diagnosed during the second or third trimester of pregnancy. The 
main characteristic is maternal hyperglycemia [1]. 
GDM increases the risk of suffering from cardiovascular and 
metabolic conditions not only in the mother but also in the offspring 
exposed to GDM in utero [2,3]. Therefore, looking for therapeutic 
strategies and investigating the mechanisms of how GDM programs 
the fetus for a higher risk of cardiovascular and metabolic diseases 
later in life is a crucial step in order to reduce the morbidity in the 
offspring of GDM patients. 
The current treatment of GDM aims to reduce the maternal 
hyperglycemia [1]. At first instance, the mother is treated with a diet, 
which is carbohydrates restricted [1,4]. In women who do not 
respond to this diet, pharmacological interventions are 
recommended [1]. Insulin therapy is mostly recommended since it 
does not cross the placenta, thereby reducing the risk of fetal 
secondary complications [1]. Although treating GDM-associated 
hyperglycemia reduces the risk of fetal complications, the risk is 
never as low as in normal/uncomplicated pregnancies [4–7]. This 
suggests that the time gap between the onset of hyperglycemia and 
the treatment of GDM irreversibly alters the fetal physiology. 
In GDM, the fetoplacental vasculature exhibits characteristics 
of endothelial dysfunction in the macro- and microvasculature [8– 
12]. There is a vicious cycle of dysregulation between NO and the 
nucleoside adenosine [13]. Nitric oxide synthesis in GDM in the 
fetoplacental vascular bed is increased due to an increased expression 
and activity of human cationic amino acid transporter 1 (hCAT-1) and 
endothelial nitric oxide (NO) synthase (eNOS) [14,15]. hCAT-1 is the 
transporter for the semi-essential amino acid L-arginine, which is 
later converted into L-citrulline and NO [16]. NO is a gasotransmitter 
that diffuses and reaches the vascular smooth muscle leading to 
vasodilation [17]. Alterations in the transport and metabolism of 
adenosine in the fetoplacental vasculature have also been shown in 
GDM. The adenosine transporter, human nucleoside equilibrative 
transporter 1 (hENT1), is mainly responsible for the bidirectional 
transport of adenosine in and out of HUVECs [18]. In HUVECs from 
GDM pregnancies, a reduction in the hENT1-mediated adenosine 
transport has been reported [19]. This results from the lower 
expression of mRNA and protein of hENT1 in response to a 
transcriptional repression mediated by NO-dependent activation of 
the transcription factor hCHOP [19]. Moreover, adenosine has 





reduced transport capacity of hENT1 [12]. The adenosine 
accumulation increases the signaling of adenosine via extracellular 
adenosine receptors and activates the transport of L-arginine, with 
the subsequent increase in NO synthesis [16]. Despite this vicious 
cycle, which results in an increased NO synthesis, in GDM; the 
fetoplacental vasculature exhibits a lower NO-dependent vasodilation 
[14]. This is likely due to a reduction of the NO bioavailability and an 
increased formation of peroxynitrite in a pro-oxidant cellular 
environment [20,21] (Fig. 1). 
In all the experimental chapters, we used HUVECs as an 
endothelial cell model. HUVECs are endothelial cells isolated from 
the umbilical vein and are thus part of the fetoplacental vasculature 
[22]. In chapter 4 we used HUVECs isolated from GDM pregnancies 
or from control pregnancies and compared these. In the other 
chapters, we used HUVECs from uncomplicated pregnancies and 
treated these HUVECs with high D-glucose (25 mmol/L) as a model 
for GDM HUVECs. As has recently been shown, treatment of 
HUVECs with high D-glucose induced endothelial dysfunction 
similar to the endothelial dysfunction seen in GDM. The dysfunction 
is characterized by alterations in endothelium derived NO, altered L- 
arginine transport, increased oxidative stress, pro-inflammation and 
altered hENT-1 transport [10,12,15,24,25]. 
In our first experimental chapter (Chapter 4), we evaluated the 
effect of GDM treatment on the expression of hENT1. We showed  
that GDM reduces the mRNA expression of hENT1 in HUVECs from 
GDM pregnancies treated with diet or with insulin therapy. However, 
in HUVECs from diet-treated GDM, this reduction in hENT1 
transcript is reflected in a reduction of hENT1 protein abundance, 
while insulin therapy seemed to restore the hENT1 protein 
expression in comparison with normal pregnancies. Since the hENT1 
mRNA expression is similar in both GDM treatments, the hENT1 
protein recovery mediated by insulin therapy might depend on 
posttranslational regulation of hENT1. However, further functional 
studies of this transporter are required to determine whether the 
protein changes are correlated with the transport capacity of hENT1. 
Previous studies have shown that insulin therapy does not restore the 
increased expression and activity of hCAT-1 and eNOS in HUVECs 
[26]. Therefore, as described in GDM treated with diet [19], in 
HUVECs from insulin therapy treated GDM, the NO-dependent 
hCHOP activation might explain the maintained reduced hENT1 
mRNA. We did not find differences in hCHOP protein abundance in 







Figure 1. Fetoplacental endothelial dysfunction in GDM. In GDM, an 
increased (⬆) nitric oxide (NO) synthesis due to expression and activity of 
endothelial NO synthase (eNOS; NOS3), human cationic amino acid transporter 
1 (hCAT-1; SLC7A1) is present in the fetoplacental endothelium. The increased 
NO activates C/EBP homolog protein 10 (hCHOP). hCHOP binds to the human 
equilibrative nucleoside transporter 1 (hENT1; SLC29A1) gene promoter, 
reducing  (⬇)  its  transcriptional  activity.  The  reduction  of  hENT1  (SLC29A1) 
expression might lead to an extracellular adenosine accumulation and activation 
of A2A adenosine receptors (AR). Activation of AR increases L-arginine transport 
with the subsequent increase in NO synthesis. In GDM human umbilical vein 
endothelial cells (HUVECs), a lower adenosine kinase (AK) activity has been 
suggested [23]. This might contribute to the adenosine accumulation observed in 
GDM. The GDM milieu increases the oxidative stress increasing the formation of 
peroxynitrite (ONOO-), reducing the NO bioavailability. This leads to a lower 
vasodilation of the fetoplacental vasculature, likely altering the placental blood 
flow. 
 
pregnancies. However, other parameters, such as the subcellular 
localization of this transcription factor (i.e. hCHOP) and the binding 
to hENT1 (SLC29A1) gene promoter may have changed and should be 
evaluated in future studies [19]. Interestingly, even though a 
normalization of maternal hyperglycemia is achieved with the GDM 
treatment, either by diet or insulin treatment, the endothelial 





indicated above, this suggests that during the initial phases of GDM, 
hyperglycemia irreversibly programs the fetal endothelial cells. If this 
endothelial functional programming remains present during adult 
life, it may partially explain the increased risk for cardiovascular and 
metabolic diseases. 
In chapter 5, we discuss the potential role of adenosine kinase 
(AK) in fetal programming in GDM. AK is an intracellular enzyme 
that converts adenosine into AMP using ATP as phosphate donor 
[27]. In vivo rat data have shown that AK may be more important in 
determining the extracellular adenosine concentrations than hENT1 
[28]. Indirect evidence suggests that in HUVECs from GDM 
pregnancies there is a lower activity of AK since adenosine 
phosphorylation was less efficient in GDM HUVECs [23]. Such a 
decreased activity of AK in GDM might be responsible (at least in 
part) for the accumulation of adenosine seen in the fetoplacental 
vasculature in GDM. 
In chapter 6 we used HUVECs incubated with high D-glucose 
as a model for GDM HUVECs and first studied AK expression in this 
model. AK subcellular localization includes the nuclear and 
cytoplasmic isoform. The expression of these two isoforms can vary 
depending on the cell type [29]. In this study, we showed for the first 
time the predominance of the AK nuclear isoform in HUVECs. 
Moreover, we also showed that the mRNA expression of AK is 
increased by high D-glucose. This was in contrary to our expectations. 
However, it may be speculated that AK activity is decreased by high 
D-glucose, resulting in a compensatory increase in AK mRNA 
transcription. 
In order to mimic the potentially reduced AK activity in 
HUVECs from GDM pregnancies, we used an inhibitor of AK, ABT-
702, which would result in an extracellular accumulation of 
adenosine [28], We thus expected an increased expression of hENT1 
in order to counteract and mobilize intracellular adenosine in 
response to the AK inhibition. However, AK inhibition did not lead to 
differences in the  total hENT1, nor  in any  of the  hENT1 
transcriptional variants at mRNA and protein level. Similarly, no 
changes in SAHH, which produces adenosine, were found in response 
to the inhibition of AK. Effects of AK inhibition were not found in 
basal D-glucose nor in high D-glucose. Furthermore, we found that 
AK inhibition did not change the gene expression of AK itself in basal 
or high D-glucose. 
In view of these results, it seems likely that the mRNA 





to high D-glucose does not depend on the increased adenosine level 
or on the reduced activity of AK, since the AK inhibition did not 
regulate the mRNA levels of these genes. Therefore, if AK activity is 
decreased in GDM HUVEC [23], it might depend on other factors 
than high D-glucose, such as the altered lipids, magnesium and/or 
potassium levels in GDM, which are indeed crucial for AK activity 
[27,30,31] and are altered in this pregnancy disease [32–34]. It is 
therefore important to evaluate the AK expression in HUVECs from 
GDM, but also in HUVECs from healthy pregnancies incubated with 
different levels of magnesium, potassium, or lipids in order to 
evaluate how AK is regulated and how it interferes in endothelial 
function in fetoplacental vasculature in GDM. 
Little is known about the transcriptional regulation of AK 
isoforms. However, in the rat AK gene, it is known that the Sp1 
transcription factor regulates the expression of the nuclear AK 
isoform [35]. In line with these results, in HUVECs exposed to high 
D-glucose an increased nuclear localization of Sp1 is reported [36]. 
Therefore, the increase in nuclear AK in HUVECs incubated  with 
high D-glucose might be explained via a Sp1-dependent mechanism. 
Nevertheless, other mechanisms have also been proposed. In the rat, 
the AK gene contains GpG islands that might be a target for DNA 
methylation [35]. Since AK gene is highly conserved among species 
[27], it is likely that in the human AK gene this mechanism 
dependent on DNA methylation may also take place. This could 
explain the predominance of the nuclear AK isoform in HUVECs. 
Our data shows a predominance of the nuclear isoform of AK. 
Since a decreased AK activity has been previously suggested in 
HUVECs from GDM pregnancies [23], which might explain the 
adenosine accumulation in GDM fetoplacental vasculature. This may 
imply that the adenosine accumulation has its origin in the nucleus of 
the cell, due to a lower n-AK activity. However, we found that the 
mRNA level of AK was increased by a high D-glucose, suggesting that 
the expression and activity of AK are independently regulated. A 
nuclear adenosine accumulation can lead to impaired 
transmethylation reactions and altered methylation-dependent gene 
expression regulation mechanisms, such as DNA and histone 
methylation [27,37], crucial for the fetal programming phenomenon 
[38]. Further studies are needed to substantiate this hypothesis in 
our model. 
In the chapter 6, we have shown that a high D-glucose level 
increases the mRNA expression of DNA methyltransferase 1 and 3A, 





adenosylhomocysteine (SAH) hydrolase (SAHH). This may result in 
altered epigenetic mechanisms under high D-glucose conditions. 
These epigenetic mechanisms can be the responsible for the 
maintenance of high D-glucose-induced alterations in the presence of 
a normal D-glucose level. 
GDM is not only associated with hyperglycemia but also with a 
proinflammatory state [39,40]. In the mother and fetus, an increase 
in circulating proinflammatory molecules has been reported [40–42]. 
Moreover, in the placental endothelium, an increased ICAM-1, 
VCAM-1 and E-selectin expression in comparison to uncomplicated 
pregnancies have been described [10,43], indicating endothelial cell 
activation. If such endothelial cells activation in the fetoplacental 
vasculature remains present until adulthood, it might, next to the 
endothelial dysfunction, also be responsible for the higher 
cardiovascular and metabolic risks observed in GDM offspring [25]. 
Therefore, the reduction of the proinflammatory environment in the 
placenta may have a beneficial impact on the vascular complications 
seen in GDM offspring later in life. Our findings in chapter 7 suggest 
that the high D-glucose itself may act as a proinflammatory stimulus 
on the endothelium, since incubation of HUVEC with high D-glucose 
increased endothelial inflammation markers, such as ICAM-1, E- 
selectin, IL-8 and TNFR1. Interestingly, AK inhibition did not change 
the high D-glucose effect in terms of the expression of the ICAM-1 
and E-selectin, indicating that the effect of high D-glucose in these 
inflammatory parameters is probably not regulated by adenosine 
levels. However, the increased TNFR1 mRNA expression triggered by 
high D-glucose was reduced by the AK inhibitor. This may suggest 
that the inhibition of AK may reduce the TNF-⍺ signaling. Therefore, 
inhibition of adenosine kinase may be beneficial for  HUVECs 
exposed to proinflammatory cytokines, as TNF-⍺. 
To further investigated the role of AK in the response of 
HUVEC to TNF-⍺ in chapter 8, we incubated HUVEC with TNF-⍺ in 
the presence of basal and high D-glucose and in the presence or 
absence of the AK inhibitor. We indeed found a reduction in the TNF- 
⍺-induced expression of endothelial proinflammatory markers and 
cytokines in the presence of AK inhibitor (ABT-702). This suggests 
that TNF-⍺ requires an active AK enzyme to exert a complete 
proinflammatory stimulus not only in basal D-glucose but also in a 
high D-glucose context. This effect of ABT-702 is likely to be 
dependent on the adenosine accumulation due to AK inhibition and 
the anti-inflammatory effects of the adenosine signaling [44]. 





reduction in histone methylation due to an adenosine accumulation 
and the interference in the transmethylation reactions [45]. In our 
studies, we did not discriminate between these 2 mechanisms, 
therefore, both mechanisms may participate in the regulation of 
proinflammatory markers in the endothelium. In view of the results, 
it seems likely that the putative lower AK activity in HUVECs from 
GDM pregnancies may be an adaptative mechanism to counteract the 
effects of the GDM-associated proinflammation in order to avoid 
more complications in the developing fetus. 
Mitochondria play a role in endothelial dysfunction in type 2 
diabetic patients [46,47]. Mitochondria are not only important for 
energy production, but they are also involved in processes like aging 
and cell faith [48,49]. In Chapter 9, we first evaluated the oxygen 
consumption rate (OCR) as a cellular metabolism marker, in 
HUVECs exposed to high D-glucose and/or TNF-⍺ in aerobic 
conditions (at 120 to 100 mmHg). Moreover, we evaluated the role of 
AK. For this, we used the AK inhibitor, ABT-702. We found that high 
D-glucose but not TNF-⍺, reduced the OCR after 24 hours 
incubation. Additionally, we found that inhibition of AK increased the 
OCR in HUVECs exposed to basal and high D-glucose and TNF-⍺, 
suggesting a beneficial role of adenosine for the cellular metabolism. 
We further evaluated whether the changes in OCR depended 
on changes in some mitochondrial parameters. Our findings suggest 
that even though there are changes in OCR induced by high D- 
glucose and ABT-702, these changes seem not to be dependent on the 
mitochondrial content, mitochondrial transcription, or mitochondrial 
biogenesis regulators. However, in this study, we did not include 
other mitochondrial functional parameters, such as the 
mitochondrial membrane potential [47]. Moreover, in future studies, 
the ATP production and consumption should be evaluated to 
elucidate whether the OCR changes are correlated with changes in  
the ATP level. Also, in our study, we evaluated the total OCR. This 
includes not only the mitochondria-dependent OCR but also the 
oxygen consumed by other processes, such as aerobic glycolysis 
[50,51]. Therefore, further studies are on the way to address the 
different fractions that constitute the total OCR in our experimental 
setup. 
A decreased cellular metabolism is a phenomenon associated 
with mitochondrial-induced apoptosis [52]. The reduced OCR 
induced by high D-glucose might imply that the fetoplacental 
vascular endothelium exposed to hyperglycemia in GDM pregnancies 





mitochondrial apoptosis and a reduced ATP production is described 
in HUVECs exposed to high levels of D-glucose [53]. This impairment 
to meet cellular metabolic requirements can accelerate endothelium 
senescence and turn over [53–55]. If this is extrapolated to the fetal 
vasculature, this reduced endothelial metabolic activity might, in 
practical terms, imply that newborns from GDM pregnancies have an 
“aged” endothelium, which likely (in part) explains the increased 
cardiovascular risk observed in adult offspring from  GDM 
pregnancies (Fig 1). Since AK inhibition increased the OCR, it seems 
 
 
Figure 2. Proposed model: Influence of GDM on the increased 
cardiovascular risk in GDM offspring. During intrauterine life, GDM might 
alter the fetoplacental endothelium via different mechanisms (prenatal cellular 
damage), such as adenosine, nitric oxide (NO), methylation reactions (Met rx), 
proinflammatory intrauterine milieu. These alterations induce endothelial 
dysfunction, endothelial inflammation, decreased metabolic activity and 
accelerated senescence increasing the cardiovascular (CV) risk. The accumulation 
of prenatal damage in addition to an unhealthy lifestyle will increase the CV risk 
and the appearance of CV events earlier in life in comparison with the offspring 





likely that the reduced AK activity as suggested in GDM-HUVECs 
might act as a compensatory mechanism in order to reduce the GDM 
impact in the endothelial metabolic activity. 
In summary, this thesis shows that main characteristic of 
GDM, as hyperglycemia and proinflammatory environment, trigger 
alterations in the fetoplacental vasculature that might explain the 
increased cardiovascular risk in GDM offspring (Fig. 2). Furthermore, 
inhibition of AK decreases some of the detrimental effects of high D-
glucose and TNF-⍺. It seems likely that the reduced AK activity in 
HUVECs from GDM, might act as an adaptative response to avoid 
more serious consequences of GDM. Understanding the mechanisms 
behind AK activity regulation might lead to novel potential 




Based on our study and the literature available it seems that 
AK plays a role in the endothelial alterations associated with GDM. 
Here we have shown that hyperglycemia might dysregulate the 
expression of key regulators of adenosine metabolism. Moreover, our 
inhibition studies suggest that the reduction in AK activity suggested 
in HUVECs from GDM might counteract some of the effects triggered 
by the intrauterine GDM milieu. Nevertheless, many questions are 
still needed to be answered. For instance, the activity of AK in high D- 
glucose conditions and in GDM still remains to be directly measured. 
Moreover, the role of each AK isoforms (i.e. nuclear and cytoplasmic) 
remains to be determined, while also the mechanism of the 
predominance of the nuclear AK in HUVECs needs to be established. 
Additionally, since AK regulates intra- but also extracellular 
adenosine levels [28], it is still required to evaluate the mechanisms 
by which AK inhibitions works. We need to evaluate whether the 
effect of AK inhibition depends on the accumulation of adenosine 
(intra- or extracellular) and whether the effects are mediated by the 
signaling through the adenosine receptors or whether the effects of 
inhibition of AK mediated by mechanisms related to dysregulation of 
methylation reactions. Also, considering that the product of the AK 
reaction is AMP, we cannot exclude the possibility that some of the 
effects observed by the inhibition of AK might depend on a reduction 
of AMP level and activation of AMP sensitive pathways. This also 
needs further investigation. 
As indicated before, there is a vicious cycle of dysregulation in 





how and at what site this vicious circle starts. It is tempting to 
hypothesize that AK activity plays a role in this process and therefore, 
it is important to establish the role of AK in this phenomenon and 
whether the accumulation of adenosine, due to a likely reduced 
activity in GDM, might play a role in this pathway. 
Finally, even though the exposure to high D-glucose in 
HUVECs is well reported in mimicking part of the GDM effects in the 
fetoplacental endothelium, we are aware that this in vitro model may 
not replicate all the effects of GDM. Therefore, in the future, similar 
analysis as performed in this thesis should be carried out in HUVECs 
isolated from GDM pregnancies and in HUVECS from healthy 
pregnancies incubated with or without high D-glucose in  the 
presence or absence of high lipids or magnesium/potassium. This 
may even better reflect the situation in GDM and may help us in 
better understanding of the mechanisms leading to fetoplacental 
endothelial dysfunction. 
Regarding the potential therapeutic implications of this study, 
we consider that the putative reduced AK activity in HUVECs from 
GDM may imply an adaptative cellular mechanism to reduce the 
effect of the GDM intrauterine environment. However, this may be a 
later effect. Since our finding suggest that hyperglycemia increases 
not only the AK mRNA but also inflammation and reduce the cellular 
metabolic activity, it is possible that in the first stage of GDM the 
pharmacological inhibition of AK may have a beneficial effect in 
reducing part of the accumulative damage produced by the 
hyperglycemia. 
The pharmacological regulation of this enzyme seems to be 
promising in the regulation of vascular inflammation and cellular 
metabolic activity. Therefore, it is tempting to study the regulation of 
AK in other conditions associated with these cellular phenomena, 
such as preeclampsia or atherosclerosis. In this respect, it is 
noteworthy to mention that in vivo animal studies in mice [56]and 
rats [57], have demonstrated the anti-inflammatory effects of this 
non-nucleoside AK inhibitor, ABT-702, which seems to be safe and 
orally active. However, studies on pregnant animals and clinical 
studies are lacking at this moment. 
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